Jia Jie Biomedical Co., Ltd. (4109.TWO)
- Previous Close
17.85 - Open
17.60 - Bid 17.60 x --
- Ask 17.70 x --
- Day's Range
17.35 - 17.70 - 52 Week Range
15.00 - 39.60 - Volume
159,012 - Avg. Volume
484,500 - Market Cap (intraday)
2.096B - Beta (5Y Monthly) --
- PE Ratio (TTM)
8.53 - EPS (TTM)
2.07 - Earnings Date --
- Forward Dividend & Yield 0.49 (2.73%)
- Ex-Dividend Date Aug 26, 2024
- 1y Target Est
--
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distribution, bidding, quotation of the products. It also involved in the wholesale of nonalcoholic beverages, candy, baked food, supplementary food, groceries, daily commodities, and cosmetics; production of water purification equipment and related parts; life and property insurance brokerage business; development and production of aquatic product technology; and development of biological products. The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.
www.jiajiebio.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 4109.TWO
View MorePerformance Overview: 4109.TWO
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4109.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4109.TWO
View MoreValuation Measures
Market Cap
2.12B
Enterprise Value
1.49B
Trailing P/E
8.61
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.68
Price/Book (mrq)
1.29
Enterprise Value/Revenue
2.93
Enterprise Value/EBITDA
6.08
Financial Highlights
Profitability and Income Statement
Profit Margin
41.48%
Return on Assets (ttm)
1.07%
Return on Equity (ttm)
15.22%
Revenue (ttm)
509.92M
Net Income Avi to Common (ttm)
211.52M
Diluted EPS (ttm)
2.07
Balance Sheet and Cash Flow
Total Cash (mrq)
629.05M
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
31.2M